Omega Therapeutics, Inc.

Omega Therapeutics, Inc. (OMGA) priced its initial public offering on Aug 2, 2021 at $17.00 per share, raising $125.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $794.3M. Goldman Sachs was lead-left underwriter, joined by Jefferies, Piper Sandler and Wedbush. Latham & Watkins advised the company and Goodwin Procter advised the underwriters.

Omega Therapeutics, Inc. is developing DNA-sequence-targeting, mRNA-encoded therapeutics on its OMEGA Epigenomic Programming platform. The platform uses epigenetics, the mechanism of gene control, and targets structures called Insulated Genomic Domains in the human genome.

Status

IPO

Ticker

OMGA

Exchange

Nasdaq Global Select

Priced

Aug 2, 2021

IPO price

$17.00

Raised

$125.8M

Market cap at IPO price

$794.3M

First filed

Jul 9, 2021

Underwriters

Goldman Sachs, Jefferies, Piper Sandler and Wedbush

Company counsel

Latham & Watkins

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.